This week’s Obesity update highlights regulatory progress, late-stage clinical wins, emerging oral therapies, and expanding metabolic disease pipelines.
In this Newsletter
Dive deeper
💊 VCT220 oral GLP-1RA Phase 3 obesity win [1] [China • 19 May 2026]
https://www.clinicaltrialsarena.com/news/vincentage-pharma-touts-phase-iii-win-for-oral-glp-1ra/
Context: Vincentage Pharma tested VCT220 in a China Phase 3 obesity trial, NCT06939296, enrolling 840 adults with obesity or overweight plus comorbidity.
Key point: VCT220 achieved 12.2% and 12.4% mean body-weight reduction at 52 weeks across two doses versus 1.3% with placebo.
Implication: May influence prescriber choice and payer reviews pending full data.
🧬 Lilly retatrutide clears TRIUMPH-1 obesity trial [2] [US • 21 May 2026]
https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss
Context: Eli Lilly evaluated retatrutide, a GIP, GLP-1, and glucagon triple receptor agonist, in adults with obesity or overweight without diabetes.
Key point: Retatrutide met primary and key secondary endpoints in TRIUMPH-1, with 25.9% and 28.3% mean weight loss at 80 weeks for 9 mg and 12 mg.
Implication: May influence prescriber choice and payer reviews pending full data.
🧪 Verdiva Bio oral obesity candidates head to ADA 2026 [3] [US • 20 May 2026]
https://www.businesswire.com/news/home/20260519669196/en/Verdiva-Bio-to-Present-Preclinical-Data-on-Investigational-Obesity-Drug-Candidates-at-the-American-Diabetes-Association-86th-Scientific-Sessions
Context: Verdiva Bio will present preclinical data at ADA 2026 for VRB-103 and VRB-104 in New Orleans on 07 Jun 2026.
Key point: VRB-103 is a once-weekly oral amylin analog, while VRB-104 is a unimolecular GLP-1 plus amylin co-agonist.
Implication: Signals pipeline investment and modality expansion.
🇰🇷 Korean GLP-1-linked MASH candidates head to EASL 2026 [4] [EU • 21 May 2026]
https://www.asiae.co.kr/en/article/2026052108072492515
Context: D&D Pharmatech, Dong-A ST, and Yuhan Corporation will present MASH and obesity-related data at EASL 2026 in Barcelona.
Key point: DD01, DA-1726, and YH25724 use different GLP-1-linked mechanisms across MASH, obesity, and liver-fat reduction programs.
Implication: Signals pipeline investment and modality expansion.
📈 CNBC frames retatrutide as Lilly’s next obesity-market pillar [5] [US • 21 May 2026]
https://www.cnbc.com/2026/05/21/eli-lilly-weight-loss-drug-retatrutide-clears-obesity-trial.html
Context: CNBC reported Lilly’s TRIUMPH-1 results and analyst expectations for retatrutide in the obesity market.
Key point: The highest retatrutide dose produced 28.3% mean weight loss at 80 weeks in completers, while about 45% achieved at least 30% weight loss.
Implication: May influence prescriber choice and payer reviews pending full data.
Why it matters
- Oral and injectable obesity assets continue to fragment by modality, mechanism, dosing, and tolerability profile.
- Retatrutide strengthens Lilly’s next-generation obesity position beyond Zepbound and Foundayo.
- VCT220 adds China-based oral GLP-1RA competition, with a planned NMPA submission.
- Amylin and GLP-1 plus amylin combinations are moving into broader obesity pipeline visibility.
- Korean biotechs are positioning differentiated GLP-1-linked mechanisms in MASH, a field still seeking clearer efficacy and fibrosis signals.
🚀 Accelerate your success. Contact us now
📂 Explore our case studies. See examples of our work.
💡 Read our insights. Learn from our latest reports and analysis
🧰 See our full range of services. Discover how we can help you.
📚 View the full Obesity archive on our research hub page
🎯 Catch up on the Top Obesity news from the past two weeks, curated by the LucidQuest team.
FAQ
What is VCT220 from Vincentage Pharma?
VCT220 is an oral GLP-1 receptor agonist for weight management. In a China Phase 3 obesity trial, it met primary endpoints and showed 12.2% to 12.4% mean weight loss at 52 weeks [1].
What is retatrutide from Eli Lilly?
Retatrutide is an investigational triple agonist targeting GIP, GLP-1, and glucagon receptors. In TRIUMPH-1, Lilly reported clinically meaningful weight loss across all tested doses [2].
How did retatrutide perform at the highest dose?
Lilly reported 28.3% mean weight loss at 80 weeks for the 12 mg dose in the efficacy estimand. CNBC reported the same figure for patients who stayed on treatment [2], [5].
What is Verdiva Bio presenting at ADA 2026?
Verdiva Bio will present preclinical data for VRB-103, an oral amylin analog, and VRB-104, a GLP-1 plus amylin co-agonist. Both are investigational obesity candidates [3].
Which Korean companies are presenting MASH data at EASL 2026?
D&D Pharmatech, Dong-A ST, and Yuhan Corporation are presenting candidates DD01, DA-1726, and YH25724. The programs use different GLP-1-linked or liver-directed mechanisms [4].
Entities / Keywords
Vincentage Pharma, VCT220, CX11, oral GLP-1RA, GLP-1 receptor agonist, obesity, NMPA
Eli Lilly, retatrutide, TRIUMPH-1, GIP, GLP-1, glucagon, triple agonist, Zepbound, Foundayo
Verdiva Bio, VRB-103, VRB-104, amylin analog, GLP-1 plus amylin co-agonist, ADA 2026
D&D Pharmatech, DD01, GLP-1 plus glucagon dual agonist, MASH
Dong-A ST, Metavia, DA-1726, oxyntomodulin analog, obesity, MASH
Yuhan Corporation, YH25724, GLP-1 plus FGF21 dual agonist
EASL 2026, ADA 2026, obesity pharmacotherapy, metabolic disease
References
- https://www.clinicaltrialsarena.com/news/vincentage-pharma-touts-phase-iii-win-for-oral-glp-1ra/
- https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss
- https://www.businesswire.com/news/home/20260519669196/en/Verdiva-Bio-to-Present-Preclinical-Data-on-Investigational-Obesity-Drug-Candidates-at-the-American-Diabetes-Association-86th-Scientific-Sessions
- https://www.asiae.co.kr/en/article/2026052108072492515
- https://www.cnbc.com/2026/05/21/eli-lilly-weight-loss-drug-retatrutide-clears-obesity-trial.html